Drug Trial Radar · NCT07052929
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Dec 15, 2025
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Astellas Gene TherapiesAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, up to 36 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene cause low or no levels of myotubularin to be made, so the muscles do not work properly. Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. Researchers have developed ASP2957 to get a healthy MTM1 gene into the body. This could help improve muscle development and function in young children with XLMTM. In this study, ASP2957 will be given to humans for the first time. ASP2957 has the healthy MTM1 gene inside a type of empty (killed) virus. The virus delivers the healthy MTM1 gene directly into cells in the body. It's possible that some boys may have antibodies to the virus if they have previously been infected with a similar virus. The antibodies could stop ASP2957 from working properly and cause an immune reaction to ASP2957. To prevent this, the boys will also be given medicines to lower the immune system. The main aims of this study are to check the safety of ASP2957, how well it is tolerated, and to find a suitable dose of ASP2957. The study was designed in 2 phases. In Phase 1, different small groups of boys will receive lower to higher doses of ASP2957. Each boy will receive a single infusion of ASP2957. Any medical problems will be recorded for each dose. This is done to find a suitable dose of ASP2957 to use in Phase 2. In Phase 2, another small group of young boys will receive a single infusion of ASP2957. The most suitable dose of ASP2957 worked out from Phase 1 will be used. The boys will be checked for up to 1 year after their single infusion of ASP2957. After this, there will be the option for the boys to join another study so they will continue to be checked longer term.
Conditions
- X-Linked Myotubular Myopathy
Interventions
ASP2957Genetic
Intravenous infusion
MethylprednisoloneDrug
Intravenous infusion
PrednisoloneDrug
Route of administration based on locally sourced product
SirolimusDrug
Route of administration based on locally sourced product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events (TEAEs)Time frame: Up to week 52
- Number of participants with adverse events of special interest (AESIs)Time frame: Up to week 52
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 52 weeks
- Number of participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 52 weeks
- Number of participants with echocardiogram (ECHO) abnormalities and/or AEsTime frame: Up to 52 weeks
- Number of participants with muscle magnetic resonance imaging (MRI) abnormalities and/or AEsTime frame: Up to 52 weeks
- Number of participants with histopathology abnormalities and/or AEs from muscle biopsyTime frame: Up to 52 weeks
- Number of participants with physical examinations abnormalities and/or AEsTime frame: Up to 52 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Lurie Children's Hospital
Chicago, Illinois · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
The University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.